Yes, was thinking the same thing. Seems the big question is "how much more effective/"safe" is Anatabine vs. others, including nivaldipine, at disrupting/targeting the single enzyme, syk." The concerning thing is that it appears that Anatabine perhaps is not completely unique in that other compounds can be effective as well. On the other hand, it is interesting that RCPI/Roskamp are choosing to present on all of these topics at upcoming conference based on their testing with Anatabine, not some other compound (including nilvadipine).
News 
Market Data 
Discover 
